{"id":3141,"date":"2015-02-19T07:30:00","date_gmt":"2015-02-19T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xps-approved-in-australia\/"},"modified":"2015-02-19T07:30:00","modified_gmt":"2015-02-19T07:30:00","slug":"xps-approved-in-australia","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/","title":{"rendered":"XPS\u2122 approved in Australia"},"content":{"rendered":"
XVIVO Perfusion has received TGA approval of XPS\u2122 (Xvivo Perfusion System). This enables sales of XPS\u2122 in Australia.<\/strong><\/div>\n<\/p>\n

With its integrated Hamilton-C2 ventilator and MAQUET CardioHelp centrifugal pump, XPS\u2122 is the market\u2019s most flexible and complete platform for EVLP (Ex Vivo Lung Perfusion) and gives the transplantation team full control of the whole process. The XPS\u2122 design means that X-rays and automatic measurement of oxygen and pH can be done while the EVLP evaluation is ongoing. XPS\u2122 has a user-friendly graphic interface, with touchscreen functionality and computer registration of the lung\u2019s values throughout the EVLP procedure, which gives data for analysis and evaluation before the final clinical decision is made whether to use the lung. <\/span><\/p>\n<\/p>\n

XVIVO Perfusion\u2019s XPS\u2122 and STEEN Solution\u2122 are the only approved products in the USA for evaluation of marginal lungs before lung transplantation. XPS\u2122 and STEEN Solution\u2122 are also CE marked in Europe. Leading clinics in the USA have obtained good clinical results when using XPS\u2122 and sales are beginning to take off in Europe. <\/span><\/p>\n<\/p>\n

Just under two hundred lung transplants are performed each year in Australia. XPS\u2122 with STEEN Solution\u2122 enables more lungs to be used for transplantation, which means that more patients with severe lung disease are given a higher quality and longer life.<\/span><\/p>\n<\/p>\n

\u201cWe are very pleased that XPS\u2122 is now available for clinical lung transplantation in Australia. With approval in Australia, XPS\u2122 has now been approved in all the large markets in the world,\u201d says Magnus Nilsson, CEO of XVIVO Perfusion.<\/span><\/p>\n<\/p>\n

February 19, 2015
Gothenburg
XVIVO Perfusion AB (publ)<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0February 19, 2015 at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

XVIVO Perfusion has received TGA approval of XPS\u2122 (Xvivo Perfusion System). This enables sales of XPS\u2122 in Australia. With its…<\/p>\n","protected":false},"template":"","class_list":["post-3141","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nXPS\u2122 approved in Australia - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XPS\u2122 approved in Australia - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion has received TGA approval of XPS\u2122 (Xvivo Perfusion System). This enables sales of XPS\u2122 in Australia. With its...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-approved-in-australia\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-approved-in-australia\\\/\",\"name\":\"XPS\u2122 approved in Australia - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-02-19T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-approved-in-australia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-approved-in-australia\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xps-approved-in-australia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XPS\u2122 approved in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XPS\u2122 approved in Australia - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/","og_locale":"en_US","og_type":"article","og_title":"XPS\u2122 approved in Australia - XVIVO","og_description":"XVIVO Perfusion has received TGA approval of XPS\u2122 (Xvivo Perfusion System). This enables sales of XPS\u2122 in Australia. With its...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/","name":"XPS\u2122 approved in Australia - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-02-19T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xps-approved-in-australia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XPS\u2122 approved in Australia"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}